ROCO
4114
Market cap362mUSD
Jul 09, Last price
33.35TWD
1D
-0.60%
1Q
7.75%
Jan 2017
143.79%
IPO
292.82%
Name
Synmosa Biopharma Corp
Chart & Performance
Notes
No notes on this company yet
Write a private note on this company, for your eyes only
Profile
Synmosa Biopharma Corporation, established in Taipei, Taiwan, in 1980, operates as a dedicated specialty pharmaceutical enterprise. The company manages the entire lifecycle of pharmaceutical and healthcare products, from research and development to manufacturing, marketing, and distribution, primarily serving the Taiwanese market under its proprietary Synmosa brand. Its diverse product portfolio addresses key therapeutic categories, including cardiovascular health, respiratory conditions, urology, sex hormone treatments, and oncology. These offerings are available in various formats such as effervescent tablets, granules, nasal sprays, metered-dose inhalers, hormonal preparations, and other specialized forms. Beyond its proprietary products, Synmosa also extends its expertise through contract manufacturing services. The company maintains a significant international presence, exporting its goods to numerous countries including South Africa, China, Hong Kong, Thailand, Singapore, Malaysia, Vietnam, Myanmar, Cambodia, Peru, Costa Rica, and Nicaragua.
Valuation
Title TWD in thousands, except ratios and share amounts | FY | FY | FY | FY | FY | FY | FY |
|---|---|---|---|---|---|---|---|
| 2025‑12 | 2024‑12 | 2023‑12 | 2022‑12 | 2021‑12 | 2020‑12 | 2019‑12 | |
| Income | |||||||
Revenues | |||||||
Cost of revenue | |||||||
Unusual Expense (Income) | |||||||
NOPBT | |||||||
NOPBT Margin | |||||||
Operating Taxes | |||||||
Tax Rate | |||||||
NOPAT | |||||||
Net income | |||||||
Dividends | |||||||
Dividend yield | |||||||
Proceeds from repurchase of equity | |||||||
BB yield | |||||||
| Debt | |||||||
Debt current | |||||||
Long-term debt | |||||||
Deferred revenue | |||||||
Other long-term liabilities | |||||||
Net debt | |||||||
| Cash flow | |||||||
Cash from operating activities | |||||||
CAPEX | |||||||
Cash from investing activities | |||||||
Cash from financing activities | |||||||
FCF | |||||||
| Balance | |||||||
Cash | |||||||
Long term investments | |||||||
Excess cash | |||||||
Stockholders' equity | |||||||
Invested Capital | |||||||
ROIC | |||||||
ROCE | |||||||
| EV | |||||||
Common stock shares outstanding | |||||||
Price | |||||||
Market cap | |||||||
EV | |||||||
EBITDA | |||||||
EV/EBITDA | |||||||
Interest | |||||||
Interest/NOPBT | |||||||